Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactococcus lactis is a lactic acid bacterium commonly used in the dairy industry, but it has also been explored as a probiotic for gastrointestinal health, including Irritable Bowel Syndrome (IBS). The scientific rationale for its use centers on its ability to modulate gut microbiota, enhance mucosal barrier function, and influence immune responses. Several preclinical studies have suggested that certain strains of L. lactis, such as L. lactis subsp. cremoris, can reduce inflammation and improve gut barrier integrity in animal models of colitis, which shares some pathophysiological similarities with IBS. Additionally, L. lactis can produce bioactive molecules that may benefit intestinal health, such as anti-inflammatory cytokines (e.g., IL-10 when genetically engineered).

However, direct clinical evidence for its effectiveness in IBS patients is limited. A few small clinical trials and pilot studies have included L. lactis as part of multi-strain probiotic preparations, with some reporting mild improvements in IBS symptoms like bloating and discomfort. Nonetheless, these studies are often underpowered, lack placebo controls, or combine L. lactis with other probiotic strains, making it difficult to isolate its specific effects. Systematic reviews and meta-analyses of probiotics in IBS rarely highlight L. lactis as a primary or well-evidenced strain.

In conclusion, while there is a plausible scientific basis and preliminary data suggesting potential benefits, robust clinical evidence is lacking, resulting in a low but not negligible rating for scientific support.

More about lactococcus lactis
More about Irritable Bowel Syndrome

Other ingredients used for Irritable Bowel Syndrome

Other health conditions supported by lactococcus lactis

Products containing lactococcus lactis